Sir, just wanted to ask a couple of questions on the U.S. business. So I just wanted to understand, when does the revenue pickup from cangrelor and dalbavancin is expected to kick in? And how is the ramp-up expected going on in the U.S. business going to h appen post tax? And how the margins are going to look post the ramp-up. So that was the first question.
Understood. Milestone revenues are related to enoxa and heparin. Is that correct?